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Key messages
What is already known about this subject?
 ► Identification of patients with SLE with severe dis-
ease, in terms of higher overall disease activity and 
greater likelihood of damage accrual, is important 
in order to facilitate timely intervention and to guide 
therapeutic strategies.
 ► Previously, higher baseline disease activity exem-
plified by a Systemic Lupus Erythematosus Disease 
Activity Index-2000 (SLEDAI- 2K) cut- off ≥10 has 
been shown to predict better responses to belimum-
ab and atacicept in patients in clinical trials.
What does this study add?
 ► We used the SLEDAI- 2K ≥10 to define high disease 
activity status (HDAS) and analysed clinical associa-
tions of HDAS in a longitudinal SLE registry.
 ► We found that patients who ever experienced HDAS 
had increased likelihood of adverse longitudinal 
outcomes including higher time- adjusted disease 
activity, flare, corticosteroid exposure and damage 
accrual.
How might this impact on clinical practice or future 
developments?
 ► HDAS is a pragmatic, simple- to- use prognostic indi-
cator that may be useful in identifying more severe 
patients, as shown by the increased overall disease 
activity, treatment burden and poorer long- term 
prognosis.
AbstrAct
Objective Disease severity in SLE is an important 
concept related to disease activity, treatment burden and 
prognosis. We set out to evaluate if high disease activity 
status (HDAS), based on ever attainment of a Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI) 
disease activity score of ≥10, is an indicator for disease 
severity in SLE.
Methods Using prospectively collected data, we assessed 
the association of HDAS with sociodemographic and 
disease characteristics and adverse clinical outcomes 
using logistic regression or generalised estimating 
equations.
Results Of 286 patients with SLE, who were observed 
for a median (range) of 5.1 years (1–10.8 years), 43.7% 
experienced HDAS at least once during the observational 
period. Autoantibody positivity, particularly anti- dsDNA 
and anti- Sm positivity, were associated with increased 
likelihood of HDAS. Age ≥45 years at diagnosis was 
associated with reduced likelihood of HDAS (p=0.002). 
Patients with HDAS had higher Physician Global 
Assessment score (>1: OR 8.1, p<0.001) and were more 
likely to meet criteria for flare (mild/moderate flare: OR 
4.4, p<0.001; severe flare: OR 17.2, p<0.001) at the 
time of experiencing HDAS. They were also more likely to 
have overall higher disease activity, as defined by time- 
adjusted mean SLEDAI- 2K score in the highest quartile (OR 
11.7, 95% CI 5.1 to 26.6; p>0.001), higher corticosteroid 
exposure (corticosteroid dose in highest quartile: OR 7.7, 
95% CI 3.9 to 15.3; p<0.001) and damage accrual (OR 2.3, 
95% CI 1.3 to 3.9; p=0.003) when compared with non- 
HDAS patients.
Conclusions HDAS is associated with more severe 
disease, as measured by higher disease activity across 
time, corticosteroid exposure and damage accrual. The 
occurrence of HDAS may be a useful prognostic marker in 
the management of SLE.
IntROduCtIOn
SLE is a relapsing–remitting, systemic auto-
immune disease that is heterogeneous in its 
presentation and natural history.1 The hetero-
geneity of SLE presents challenges for its diag-
nosis and management, as well as the evalu-
ation of potential new treatments.2 3 Despite 
some improvements in the survival of patients 
with SLE over recent decades, the increased 
mortality and morbidity experienced by 
patients with SLE when compared with the 
general population is a major concern for 
healthcare providers.4–7
Several studies have identified a number 
of non- reversible prognostic factors that 
are associated with increased mortality in 
SLE such as gender, damage accrual and 
non- European ethnicity.4 6 8–11 However, 
early identification of patients destined 
for a more severe disease course in order 
to facilitate more timely intervention and 
to guide therapeutic strategies could have 
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Table 1 Differences in baseline patient characteristics by HDAS
Baseline parameter
Descriptive statistics Association of parameter 
with ever meeting HDAS 
definition*









  Female 140 (87.0) 106 (84.8) 1
  Male 21 (13.0) 19 (15.2) 1.2 (0.6 to 2.3; 0.602)
Ethnicity
  Caucasian 90 (55.9) 60 (48.0) 1
  Asian 57 (35.4) 57 (45.6) 1.5 (0.9 to 2.5; 0.106)
  Other/missing 14 (8.7) 8 (6.4) 0.9 (0.3 to 2.2; 0.745)
Disease characteristics
Age at diagnosis (years)
  <18 4 (19.1) 6 (31.6) 1
  ≥18 to <45 7 (33.3) 7 (36.8) 0.5 (0.3 to 1.1; 0.088)
  ≥45 10 (47.6) 6 (31.6) 0.3 (0.1 to 0.6; 0.002)
Time since diagnosis of SLE (years)
  ≤5 96 (59.6) 63 (50.4) 1
  >5 65 (40.4) 62 (49.6) 1.5 (0.9 to 2.3; 0.120)
ACR diagnostic criteria Per ACR criterion met:
  Median no of criteria met at enrolment 4 (2–9) 5 (3–9) 1.7 (1.4 to 2.0; <0.001)
  Specific criteria met:
   ANA 154 (95.7) 122 (97.6) 1.8 (0.5 to 7.3; 0.381)
   Arthritis (non- erosive) 110 (68.3) 86 (68.8) 1.02 (0.6 to 1.7; 0.931)
   Discoid rash 16 (9.9) 15 (12.0) 1.2 (0.6 to 2.6; 0.578)
   Haematological disorder 75 (46.6) 71 (56.8) 1.5 (0.1 to 0.9; 0.087)
   Immunological disorders 118 (73.3) 113 (90.4) 3.4 (1.7 to 6.8; <0.001)
   Malar rash 66 (41.0) 57 (45.6) 1.2 (0.8 to 1.9; 0.435)
   Neurological disorder 6 (3.7) 14 (11.2) 3.3 (1.2 to 8.7; 0.019)
   Oral ulcers 56 (34.8) 48 (38.4) 1.2 (0.7 to 1.9; 0.528)
   Photosensitivity 58 (36.0) 39 (31.2) 0.8 (0.5 to 1.3; 0.393)
   Renal disorder 37 (23.0) 71 (56.8) 4.4 (2.6 to 7.3; <0.001)
   Serositis 41 (25.5) 53 (42.4) 2.2 (1.3 to 3.6; 0.003)
Autoantibody positivity†
ANA 118 (73.3) 119 (95.2) 7.2 (3.0 to 17.6; <0.001)
  Anti- dsDNA 87 (54.0) 112 (89.6) 7.3 (3.8 to 14.1; <0.001)
  Anti- La 30 (18.6) 36 (28.8) 1.8 (1.0 to 3.1; 0.044)
  Anti- RNP 28 (17.4) 38 (30.4) 2.1 (1.2 to 3.6; 0.010)
  Anti- Ro 57 (35.4) 64 (51.2) 1.9 (1.2 to 3.1; 0.008)
  Anti- Sm 12 (7.5) 30 (24.0) 3.9 (1.9 to 8.0; <0.001)
Anti- phospholipid antibodies 61 (37.9) 60 (48.0) 1.5 (0.9 to 2.4; 0.087)
  Anti- beta2- GPI 17 (10.6) 18 (14.4) 1.4 (0.7 to 2.9; 0.327)
  Anti- cardiolipin 56 (34.8) 54 (43.2) 1.4 (0.9 to 2.3; 0.147)
  Lupus anticoagulant 13 (8.1) 15 (12.0) 1.6 (0.7 to 3.4; 0.271)
Other serology
Continued
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Baseline parameter
Descriptive statistics Association of parameter 
with ever meeting HDAS 
definition*




At least one 
occurrence of HDAS
(n=125)
  Anti- neutrophil cytoplasmic antibody (any) 12 (7.5) 17 (13.6) 2.0 (0.9 to 4.3; 0.092)
  Positive direct antiglobulin test 30 (18.6) 37 (29.6) 1.8 (1.1 to 3.2; 0.031)
  Rheumatoid factor 42 (26.1) 39 (31.2) 1.3 (0.8 to 2.2; 0.342)
Hypocomplementemia (low C3 or C4) 66 (41.0) 82 (65.6) 2.7 (1.7 to 4.5; <0.001)
*Reference group for OR is the absence of the parameter where the reference group is not specified.
†Limited to autoantibodies with a prevalence of ≥10%. Note that if we adjust for anti- dsDNA autoantibody positivity when assessing the 
association of other autoantibodies with HDAS, only anti- dsDNA and anti- Sm remain associated with increased odds of experiencing HDAS 
(data not shown).
ACR, American College of Rheumatology; HDAS, high disease activity state, SLEDAI- 2K ≥10.
Table 1 Continued
Table 2 Disease characteristics by HDAS status at each visit
Disease parameter
Descriptive statistics by HDAS visit 
status





(n=741) OR‡ (95% CI; p value)
PGA in highest quartile (PGA >1) 459 (9.3) 421 (56.8) 8.1 (6.1 to 10.8; <0.001)
SFI flare status       
  Mild/moderate flare 771 (15.6) 307 (41.4) 4.4 (3.5 to 5.4; <0.001)
  Severe flare 171 (3.5) 290 (39.1) 17.2 (13.6 to 21.6; <0.001)
Immunomodulatory medications being taken at time of visit*   
  Hydroxychloroquine 4235 (85.8) 642 (86.6) 1.0 (0.8 to 1.2; 0.963)
  Immunosuppressant† 3094 (62.6) 597 (80.6) 0.9 (0.8 to 1.0; 0.083)
  Prednisolone 2962 (60.0) 651 (87.9) 1.3 (1.1 to 1.5; 0.003)
  Prednisolone dose >7.5 mg/day 1114 (22.6) 508 (68.6) 2.5 (2.0 to 3.1; <0.001)
*Restricted to medications taken by ≥10% of patients.
†Including methotrexate, azathioprine, 6- mercaptopurine, leflunomide, cyclophosphamide and mycophenolate.
‡OR calculated using penalised maximum- likelihood logistic regression. Interpret OR with caution given rareness of event.
HDAS, high disease activity state; PGA, Physician Global Assessment; SFI, SELENA flare index.
considerable benefit. In clinical trials and other studies, 
baseline disease activity, typically defined using the 
Systemic Lupus Erythematosus Disease Activity Index-
2000 (SLEDAI- 2K) score,12 has often been used as a 
means of identifying patients with more active disease at 
enrolment.13–17 Recently, a SLEDAI- 2K disease activity 
score of ≥10 has also been shown to predict responses to 
treatment with belimumab16 and atacicept,15 suggesting 
that this cut- off may also identify a subgroup of patients 
more likely to benefit from costly biologic treatment. 
However, focusing only on the baseline disease activity 
score may miss a subset of severe patients who expe-
rience active disease at other timepoints, particularly 
given the relapsing–remitting nature of SLE.
In this study, we defined high disease activity status 
(HDAS) based on patients who ever attain a SLEDAI- 2K 
of ≥10, and investigated the clinical associations of HDAS 
in a longitudinal cohort of patients with SLE to evaluate if 
HDAS identifies a subgroup of patients with SLE who are 
at risk of worse outcomes.
MetHOds
study design, setting and participants
The Monash Lupus Clinic is a specialist outpatient clinic 
based at Monash Medical Centre in Melbourne, Australia. 
As a centre of the Australian Lupus Registry and Biobank,18 
the clinic prospectively collects data including sociode-
mographic details, pathology and treatment information 
and SLE- specific disease activity and damage assessments. 
To be enrolled, patients must meet the American College 
of Rheumatology (ACR)19 or the Systemic Lupus Interna-
tional Collaborating Clinics (SLICC)20 SLE Classification 
Criteria. The current study was limited to patients who 
had been followed for at least 1 year between April 2007 
and February 2018, and had sufficient data available to 
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Manifestations with a weighting of 8
  Seizure 0.00 0.40
  Psychosis <0.1 1.20
  Organic brain syndrome 0.00 2.60
  Visual disturbance <0.1 1.40
  Cranial nerve disorder 0.20 1.40
  Lupus headache 0.00 1.40
  Stroke/CVA 0.00 0.00
  Vasculitis 0.04 8.60
At least one 8- point 
manifestation
0.30 15.90
Manifestations with a weighting of 4
  Arthritis 5.10 15.80
  Myositis 0.20 2.60
  Urinary casts 0.10 3.90
  Haematuria 1.70 53.60
  Proteinuria 16.50 75.60
  Pyuria 0.70 33.50
Manifestations with a weighting of 2
  Rash 11.80 34.70
  Alopecia 3.70 11.90
  Mucosal ulcers 2.50 8.10
  Pleurisy 1.20 5.40
  Pericarditis 0.20 1.40
  Low complement 56.60 86.90
  Increased DNA binding 54.50 84.50
Manifestations with a weighting of 1
  Thrombocytopenia 2.10 2.30
  Leucopenia 4.90 4.10
  Fever 0.10 1.60
CVA, cerebrovascular accident; HDAS, high disease activity status; 
SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
determine if they had ever experienced HDAS. All partic-
ipants provided written informed consent for their partic-
ipation.
sociodemographic variables
Demographic details (date of birth, sex, ethnicity) were 
captured at enrolment. Ethnicity was captured in line with 
the Australian Bureau of Statistics Australian Standard 
Classification of Cultural and Ethnic Groups.21
sLe-related clinical variables
Diagnostic assessments and autoantibody positivity were 
assessed at enrolment. Date of diagnosis refers to when 
the diagnosis of SLE was confirmed by a specialist. At 
each visit, SLE disease activity was measured using the 
SLEDAI- 2K,12 the Physician Global Assessment (PGA) 
(0–3) and the SELENA flare index (SFI).22 A time- 
adjusted mean SLEDAI (AMS)23 was calculated as an 
overall measure of disease activity over the observation 
period. SLEDAI- 2K manifestations occurring during the 
observation period were also classified by body system. 
Accrual of damage since the onset of SLE or during the 
observation period was measured using the SLICC/ACR 
Damage Index (SDI).24 Time- adjusted mean and cumu-
lative drug doses for glucocorticoid and other immu-
nomodulatory medications were calculated in a similar 
manner to the AMS calculation.23
High disease activity status
HDAS is defined when a patient experienced disease 
activity, measured by SLEDAI- 2K score ≥10 on at least one 
occasion during the observation period.
statistical methods
All analyses were carried out using StataSE V.14.2 (Stat-
aCorp, College Station, TX, USA).
Descriptive statistics were used to describe the charac-
teristics of patients categorised by HDAS. Bivariate tests 
(eg, Mann- Whitney U test) were used for simple bivariate 
comparisons. Logistic regression was used to assess the 
association of baseline patient characteristics with HDAS 
and the association of experiencing HDAS with longitu-
dinal outcomes. Generalised estimating equations (GEEs) 
based on an exchangeable correlation matrix and using 
robust SE estimation was used to assess the association 
of being in HDAS with particular disease characteristics 
at the time of experiencing HDAS. Penalised maximum- 
likelihood logistic regression was used instead of GEE 
where a disease characteristic was rare (frequency ≤2%).
The likelihood ratio test was used to confirm that the 
association of any continuous exposure or confounding 
variables with the log odds of the outcome variable was 
sufficiently linear for the variable to be modelled as a 
continuous variable. Missing data were excluded from 
the analyses. Most variables had a low level of missing 
data. The major source of missing data was missing data 
for SLEDAI- 2K calculation (16.4% of SLEDAI- 2K assess-




Of 347 patients with SLE on whom data were available, 
286 (82.4%) met the criteria for inclusion in the anal-
ysis (followed for at least 1 year and had sufficient data 
to determine if they ever met the criteria for HDAS). Of 
the patients excluded from the analysis, the majority (60; 
98.4%) were excluded because they had been followed 
for <1 year. The patients included in the analysis were 
followed for a median of 5.1 years (range, 1–10.8 years).
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Table 4 Association of SLEDAI-2K manifestation with HDAS after exclusion from SLEDAI calculation†
SLEDAI manifestations
Non- HDAS visit with 
adjustment n/total (%)
HDAS visit with 
adjustment n/total (%) OR (95% CI; p value)*
Manifestations with a weighting of 8
  Seizure 1/4940 (0.02) 2/740 (0.27) *
  Psychosis 7/4946 (0.14) 3/734 (0.41) 2.9 (0.6 to 10.4; 0.125)
  Organic brain syndrome 12/4951 (0.24) 7/729 (0.96) 4.0 (1.5 to 10.0; 0.004)
  Visual disturbance 9/4948 (0.18) 2/732 (0.27) 1.5 (0.2 to 5.8; 0.604)
  Cranial nerve disorder 16/4955 (0.32) 3/725 (0.41) 1.3 (0.3 to 3.8; 0.71)
  Lupus headache 10/4949 (0.2) 0/731 (0) *
  Stroke/CVA 0/4949 (0) 0/741 (0) *
  Vasculitis 46/4985 (0.92) 20/695 (2.88) 3.2 (1.8 to 5.3; <0.001)
Manifestations with a weighting of 4
  Arthritis 312/5521 (5.94) 57/429 (13.29) 1.4 (1.0 to 1.8; 0.035)
  Myositis 16/4955 (0.32) 11/725 (1.52) 4.7 (2.1 to 10.1; <0.001)
  Urinary casts 9/4948 (0.18) 27/732 (3.69) 28.7 (13.3 to 71.5; <0.001)
  Haematuria 266/5205 (5.11) 217/475 (45.68) 65.1 (50.6 to 84.7; <0.001)
  Proteinuria 1112/5368 (20.72) 262/312 (83.97) 5.4 (4.4 to 6.6; <0.001)
  Pyuria 96/5035 (1.91) 185/645 (28.68) 19.2 (14.8 to 25; <0.001)
Manifestations with a weighting of 2
  Rash 682/5166 (17.2) 159/541 (30.93) 2.1 (1.7 to 2.6; <0.001)
  Alopecia 211/5150 (4.1) 60/530 (11.32) 2.1 (1.5 to 2.8; <0.001)
  Mucosal ulcers 136/5075 (2.68) 46/605 (7.6) 2.4 (1.7 to 3.4; <0.001)
  Pleurisy 64/5003 (4.87) 33/677 (4.87) 3.6 (2.3 to 5.5; <0.001)
  Pericarditis 10/4949 (0.2) 9/731 (1.23) 6.1 (2.4 to 15.1; <0.001)
  Low complement 2964/5166 (57.38) 474/514 (92.22) 3.5 (2.8 to 4.5; <0.001)
  Increased DNA binding 2852/5166 (55.2) 465/514 (90.47) 3.2 (2.6 to 4.0; <0.001)
Manifestations with a weighting of 1
  Thrombocytopenia 105/5044 (2.08) 15/636 (2.36) 1.0 (0.5 to 1.6; 0.867)
  Leucopenia 246/5185 (4.74) 28/495 (5.66) 0.8 (0.5 to 1.1; 0.16)
  Fever 8/4947 (0.16) 11/733 (1.5) 9.3 (3.8 to 24.1; <0.001)
*Too few data points to calculate OR.
†In this analysis, the SLEDAI- 2K score was re- calculated based on all SLEDAI manifestations excluding the current SLEDAI- 2K manifestation 
being investigated. Consequently, the total number of HDAS and non- HDAS visits may differ between SLEDAI manifestations.
CVA, cerebrovascular accident; HDAS, high disease activity status; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
High disease activity status
A total of 125 patients (43.7 %) had HDAS during the 
observation period. Over three quarters of HDAS patients 
(76.8%) experienced HDAS at multiple visits. Among 
patients experiencing at least one occasion of HDAS, the 
median number of HDAS visits experienced was 3 (range, 
1–53).
The first HDAS visit was experienced a median of 3.6 
months after enrolment (range, 0–8.9 years). Only a third 
(33.6%) of HDAS patients experienced HDAS at their 
baseline visit. Compared with patients who never experi-
enced HDAS, HDAS patients were followed for a longer 
duration (median of 5.8 vs 4.6 years, p<0.001) and had 
a higher number of patient visits during the observation 
period (median of 27 vs 14 visits, p<0.001).
An alternative definition of severe disease based on 
the presence of major organ involvement (at least one of 
renal, neurological, cardiovascular or respiratory system 
involvement) and requirement treatment with >7.5 mg/
day corticosteroids or immunosuppressants has been 
proposed and used in the Lupus erythematosus Cost 
of Illness in Europe (LUCIE) study25 26 We found that 
almost all (92%) of HDAS patients of our cohort would 
fulfil this definition assessing the criteria over the course 
of the observation period. This is in contrast to only 54% 
of the patients labelled as severe in the LUCIE study who 
had SLEDAI ≥10 and hence fulfil the definition of HDAS 
at baseline. HDAS is a simpler measure to communicate 
regarding disease severity and compares well to other 
definitions of disease severity.
Koelmeyer R, et al. Lupus Science & Medicine 2020;7:e000372. doi:10.1136/lupus-2019-0003726
Lupus Science & Medicine
Table 5 Association of HDAS with longitudinal SLE outcomes
Longitudinal parameter
Descriptive statistics by HDAS
Number (column %)
Association of ever 
experiencing HDAS with 
longitudinal SLE outcome*
OR (95% CI; p value)HDAS (n=161) No HDAS (n=125)
AMS in highest quartile (AMS ≥4.3) 9 (5.6) 59 (47.2) 11.7 (5.1 to 26.6; <0.001)†
SFI flare occurrence   
  No of mild/moderate flares in highest quartile (≥7) 9 (5.6) 60 (48.0) 17.3 (7.4 to 40.5; <0.001)
  No of severe flares in highest quartile (≥3) 6 (3.7) 50 (40.0) 14.9 (6.0 to 36.9; <0.001)
SDI damage accrual   
Accrued damage during observation period 45 (28.0) 66 (52.8) 2.3 (1.3 to 3.9; 0.003)
  Within a specific organ system   
   Musculoskeletal 16 (9.9) 23 (18.4) 1.4 (0.7 to 2.9; 0.365)
   Skin 8 (5.0) 18 (14.4) 2.4 (1.0 to 6.0; 0.053)
   Neuropsychiatric 5 (3.1) 10 (8.0) 2.2 (0.7 to 6.8; 0.170)
   Ocular 8 (5.0) 8 (6.4) 1.1 (0.4 to 3.1; 0.879)
   Cardiovascular 11 (6.8) 10 (8.0) 0.8 (0.3 to 2.0; 0.617)
   Renal 4 (2.5) 20 (16.0) 7.2 (2.4 to 22.0; 0.001)
   Peripheral vascular 6 (3.7) 9 (7.2) 1.4 (0.4 to 4.1; 0.593)
   Pulmonary 2 (1.2) 6 (4.8) 3.0 (0.6 to 15.5; 0.199)
   Gastrointestinal 2 (1.2) 4 (3.2) 2.4 (0.4 to 13.6; 0.336)
   Other 8 (5.0) 10 (8.0) 1.4 (0.5 to 3.7; 0.530)
Immunomodulatory drug doses: cumulative dose over observation period in highest quartile‡
  Prednisolone 14 (8.7) 57 (45.6) 7.7 (3.9 to 15.3; <0.001)
  Hydroxychloroquine 31 (19.3) 40 (32.0) 0.9 (0.4 to 2.0; 0.819)
  Methotrexate 35 (21.7) 31 (24.8) 1.1 (0.6 to 1.9; 0.798)
  Azathioprine/6- mercaptopurine 30 (18.6) 41 (32.8) 1.7 (0.9 to 3.0; 0.076)
  Mycophenolate 13 (8.1) 58 (46.4) 9.4 (4.8 to 18.5; <0.001)
*Adjusted for patient observation time. Reference category for OR: those who did not experience HDAS during the observation period.
†OR also adjusted for cumulative prednisolone dose.
‡Limited to immunomodulatory medication taken by ≥10% of patients. Cut- offs for cumulative doses within the highest quartile were 
prednisolone ≥13.9 g, hydroxychloroquine ≥805.7 g, methotrexate ≥44.9 mg, azathioprine/6- mercaptopurine ≥49.9 g and mycophenolate 
≥889.0 g.
AMS, adjusted mean Systemic Lupus Erythematosus Disease Activity Index; HDAS, high disease activity status; SDI, Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology Damage Index; SFI, SELENA flare index.
Baseline patient characteristics and association with HdAs
Table 1 provides an overview of the association of base-
line sociodemographic and clinical variables with HDAS 
occurring during the observation period. Patients with 
immunological, serositis, renal disease or neurological 
manifestations, as captured by historical organ involve-
ment on ACR classification criteria at enrolment, were 
more likely to have at least one occurrence of HDAS 
during the period of observation. Patients positive for a 
number of autoantibodies, including anti- dsDNA autoan-
tibodies or anti- Sm autoantibodies, were more likely to 
experience HDAS compared with patients not positive for 
these autoantibodies (table 1). Patients with low comple-
ment C3 or C4 at baseline were also more likely to expe-
rience HDAS, but there was no association with antiphos-
pholipid antibodies. Patients diagnosed at age ≥45 years 
also had significantly lower odds of experiencing HDAS 
compared with patients diagnosed at age <18 years.
Association of HdAs with disease characteristics
Table 2 outlines the association of HDAS with disease 
parameters at the time of the HDAS visit. Patients with 
HDAS had higher PGA (PGA>1: OR 8.1, p<0.001) and 
were more likely to meet criteria for flare (mild/moderate 
flare: OR 4.4, p<0.001; severe flare: OR 17.2, p<0.001) at 
the time of experiencing HDAS. Patients were also more 
likely to be taking prednisolone at a HDAS visit compared 
with a non- HDAS visit (see table 2).
The clinical manifestations at the time of HDAS were 
varied and not restricted to manifestations that carry a 
heavier weight in the SLEDAI- 2K scoring system. Table 3 
presents the frequency of each clinical manifestation 
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present in non- HDAS and HDAS visits and the breadth of 
organ manifestations in HDAS visits was noted across most 
domains including ones that carried a lower weighting in 
the SLEDAI- 2K scoring system such as arthritis and rash. 
After serological activity, the most common manifesta-
tions at the time of experiencing HDAS included renal 
manifestations (proteinuria, haematuria, pyuria), rash, 
arthritis, alopecia and vasculitis.
As the definition of HDAS includes variables of 
SLEDAI- 2K, the clinical profile of patients identified 
using a SLEDAI- 2K cut- off is influenced by the SLEDAI- 2K 
domains involved and their weightings. We performed 
additional analysis to examine the strength of the associa-
tions of each clinical variable with HDAS, after removing 
that variable from the calculation of HDAS. Table 4 
presents the OR for the association of each disease 
manifestation with HDAS after this exclusion. A similar 
distribution of the SLEDAI- 2K fields spanning across 
different weighting categories was observed to that shown 
in table 3.
Association of HdAs with longitudinal outcomes
Table 5 presents the associations of experiencing HDAS at 
any time with longitudinal outcomes. HDAS patients were 
more likely to have high disease activity across the period 
of observation, as defined by AMS score in the highest 
quartile (≥4.3) after adjusting for cumulative predniso-
lone dose and observation time (OR 11.7, p>0.001). The 
median AMS was 4.1 (range, 0–13.9) in patients with 
any occurrence of HDAS, compared with 1.5 (range, 
0–5.1) for non- HDAS patients. HDAS patients were also 
more likely to experience mild/moderate flares (OR 
17.3, p<0.001) or severe flares (OR 14.9, p<0.001) and 
to accrue damage (OR 2.3, p=0.003) during the obser-
vation period. HDAS patients were particularly more 
likely to accrue renal damage (OR 7.2, p=0.001). HDAS 
patients were also more likely to be exposed to higher 
cumulative doses of prednisolone and mycophenolate, as 
demonstrated by increased odds of being in the highest 
quartile of medication exposure within the entire cohort 
(prednisolone OR 7.7, p<0.001; and mycophenolate OR 
9.4, p<0.001, respectively) (see table 3). Over the period 
of observation, when compared with non- HDAS patients, 
HDAS patients were more likely to present with neuropsy-
chiatric, renal or vasculitis disease activity (OR >10, data 
not shown).
Additional models were run to assess the impact 
of cumulative prednisolone dose and renal disease 
activity in explaining the association between HDAS 
and damage accrual and whether adjusting for patient 
demographics attenuated the association of HDAS with 
adverse outcomes. The association between HDAS and 
overall damage accrual remained after adjusting for renal 
disease activity during the observation period but disap-
peared after adjusting for cumulative prednisolone dose; 
the association between HDAS and renal damage accrual 
remained significant after adjusting for prednisolone 
(OR 5.2; 95% CI 1.60 to 17.0). Adjusting for sex and age 
at diagnosis with an interaction term fitted between sex 
and age at diagnosis did not significantly alter the associ-
ations reported in table 5.
dIsCussIOn
This study demonstrated that HDAS is a useful disease 
severity measure that takes into account of past or current 
disease activity and is also associated with important 
adverse outcomes such as treatment burden and prog-
nosis. While there have been several disease severity 
indices proposed, their definitions are generally compli-
cated.27–29 One of the more recently used severity indices 
incorporates specific organ involvement, together with 
the need for treatment with corticosteroids or immuno-
suppressants.25 26 Our study has suggested a simple disease 
activity cut- off such as SLEDAI ≥10, which has been used 
to evaluate subsets of responders in recent SLE clinical 
trials,16 can identify a population of patients with SLE 
who are likely to have more severe disease. HDAS attain-
ment on even a single occasion was associated with more 
severe disease and worse outcomes over time, as shown 
by higher overall disease activity, increased likelihood of 
flares, higher use of prednisolone and immunosuppres-
sion, and increased damage accrual.
Disease activity measurement is already an integral part 
of recommendations for disease management in SLE.30 31 
While there are several validated disease activity indices 
available,32 33 the SLEDAI has been widely used32 34 and 
has been shown to be sensitive to change in response to 
patient treatment and disease course.35 Disease activity 
scoring systems such as SLEDAI- 2K allow for evalua-
tion of the breadth of organ involvement, but through 
weighting attempt to take into account differences in 
implied severity of different manifestations.12 Kasitanon 
et al reported that having a SLEDAI- 2K score ≥10 at the 
first visit was associated with increased mortality; however, 
in this study the association was lost when they adjusted 
for patient characteristics such as sex, ethnicity and age 
at diagnosis.14 Other studies of different disease activity 
instruments support the notion that high disease activity 
predicts short- term mortality.36
The clinical diversity of SLE presents a major challenge 
for clinicians in terms of providing long- term prognostic 
information for patients. The use of a prognostic indi-
cator that is linked to a global disease activity measure 
may be a useful adjunct to routine clinical practice.30–32 37 
Here, we have shown that attainment of HDAS at any time 
point provides useful prognostic information, given its 
association with a range of disease severity measures (ie, 
higher AMS, flares and damage accrual), and that these 
associations remained after adjustment for patient demo-
graphic characteristics. In addition, we have found differ-
ences between HDAS and non- HDAS patients in terms 
of medication exposure, including cumulative doses of 
prednisolone and immunosuppressants. The associa-
tion between HDAS and overall damage accrual was lost 
after adjusting for cumulative prednisolone dose. While 
Koelmeyer R, et al. Lupus Science & Medicine 2020;7:e000372. doi:10.1136/lupus-2019-0003728
Lupus Science & Medicine
this might be consistent with reports that corticosteroid 
use plays a role in damage accrual, it may also be due to 
collinearity between disease activity and steroid use.38 39
Patients who experience HDAS may be a clinically 
distinct subgroup. These patients were more likely to be 
diagnosed at an early age and be positive for multiple 
autoantibodies. Even though HDAS patients were more 
likely to experience neuropsychiatric, renal and vasculitis 
disease activity over time, it was possible to achieve HDAS 
based on activity in multiple low- weighted organ manifes-
tations, and almost all domains of SLEDAI, regardless of 
weight, were observed more frequently in HDAS patients.
There are some limitations of this study. These include 
that it was carried out in a single centre and is a retrospec-
tive study, although of prospectively collected data.
This study provides evidence suggesting any occur-
rence of HDAS, defined using a simple SLEDAI- 2K cut- 
off of 10 or higher, may be a useful prognostic indicator 
for SLE. HDAS is easy to calculate, and provides infor-
mation regarding likelihood of future disease activity, 
flares, medication burden and damage accrual over time. 
Further studies should explore the prognostic value of 
HDAS in different cohorts, as it has potential to be used 
outside the clinical trial setting in identification of patients 
who are at higher risk of adverse outcomes. Confirmation 
of the utility of HDAS in observational cohorts could 
provide supported for tailored intervention in this group 
of patients.
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